This post was originally published on this site People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to the hospital twice as often as people without the condition, new research suggests. This may be helpful in identifying people with MGUS and, by extension, aid in early…
This post was originally published on this site Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is for Adcetris in combination with CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy, and is for people with previously untreated…
This post was originally published on this site The Arthur M. Blank Family Foundation has given $1 million to the Icahn School of Medicine at Mount Sinai‘s urology department to support research into prostate cancer. Together with an earlier foundation gift of $500,000, the money will support the New York school’s Prostate Cancer Program, whose mission is to…
This post was originally published on this site BeyondSpring’s single-blinded trial design, in which patients are unaware of the treatment they receive, effectively prevented participants from prematurely withdrawing from the company’s DUBLIN-3 study due to dissatisfaction with their treatment allocation, an analysis shows. The findings were presented in a poster, titled “Validation of a Single-Blinded…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic test for identifying advanced breast cancer patients with a PIK3CA mutation suitable for treatment with Piqray (alpelisib). Piqray was approved in May, in combination with Faslodex (fulvestrant), for postmenopausal women and…
This post was originally published on this site Common treatments for diabetes don’t appear to mask or reduce levels of a prostate cancer marker in the blood. Rather, the lower rates of prostate cancer detected in men with diabetes might be because they are less likely to undergo prostate biopsies, a large population-based study from…
This post was originally published on this site With a $544,360 developmental grant from the U.S. Department of Defense (DoD), four research teams are joining efforts to identify biomarkers of ovarian cancer with a goal of detecting the disease earlier or before it even develops. The collaboration, named DoD and SPORE Ovarian Cancer Omics Consortium,…
This post was originally published on this site Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common genetic abnormality called t(11;14), new Phase 1/2 data show. The combination reduced tumor burden in nearly all — 92%…
This post was originally published on this site Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who received a stem cell transplant from an unrelated donor, the company has announced. The designation intends to accelerate…
This post was originally published on this site The lungs of patients with sarcoidosis are burdened with a more active subset of immune T-cells, called mucosal-associated invariant T (MAIT) cells, a study reports. The activity of these MAIT cells correlates with worse disease, supporting their potential as therapeutic targets, the researchers said. The study, “Activation…
